Wedbush Raises Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $176.00

Key Points

• Wedbush raised its price target on Neurocrine to $176 (from $166) and kept an "outperform" rating, implying roughly a 30% upside from the current share price.
• Neurocrine reported stronger-than-expected recent results driven by INGREZZA (net product sales ahead of estimates), reaffirmed 2026 INGREZZA guidance of $2.7–$2.8B, and announced the acquisition of Soleno to add VYKAT XR while advancing pipeline programs (Phase 2 for NBI‑1117570).
• Analysts hold a consensus of "Moderate Buy" with an average target around $180.95, but the stock trades at a premium (P/E ~29), leaving shares exposed if growth or execution slows.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) had its target price increased by Wedbush from $166.00 to $176.00 in a report released on Wednesday,Benzinga reports. The firm currently has an "outperform" rating on the stock. Wedbush's price objective would indicate a potential upside of 30.31% from the company's current price.

A number of other equities research analysts also recently weighed in on the stock. Wall Street Zen upgraded shares of Neurocrine Biosciences from a "buy" rating to a "strong-buy" rating in a research report on Saturday, April 25th. Royal Bank Of Canada dropped their price target on shares of Neurocrine Biosciences from $180.00 to $177.00 and set an "outperform" rating for the company in a research report on Thursday, February 12th. Needham & Company LLC reiterated a "buy" rating and issued a $185.00 price target on shares of Neurocrine Biosciences in a research report on Monday, April 6th. Truist Financial dropped their price target on shares of Neurocrine Biosciences from $169.00 to $140.00 and set a "buy" rating for the company in a research report on Tuesday, February 17th. Finally, Wells Fargo & Company dropped their price target on shares of Neurocrine Biosciences from $180.00 to $175.00 and set an "overweight" rating for the company in a research report on Friday, February 13th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $180.95.

Get Neurocrine Biosciences SMS alerts:

Sign Up

Neurocrine Biosciences Trading Up 0.7%

NASDAQ NBIX opened at $135.06 on Wednesday. Neurocrine Biosciences has a 1-year low of $115.66 and a 1-year high of $160.18. The company has a 50 day moving average of $130.37 and a 200-day moving average of $137.72. The company has a market cap of $13.58 billion, a price-to-earnings ratio of 28.98, a PEG ratio of 0.67 and a beta of 0.34.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last released its quarterly earnings results on Wednesday, February 11th. The company reported $1.88 earnings per share for the quarter, missing analysts' consensus estimates of $2.36 by ($0.48). Neurocrine Biosciences had a net margin of 16.73% and a return on equity of 16.48%. The business had revenue of $805.50 million during the quarter, compared to analyst estimates of $804.21 million. During the same quarter in the previous year, the firm posted $1.69 earnings per share. The firm's quarterly revenue was up 28.3% on a year-over-year basis. On average, equities research analysts forecast that Neurocrine Biosciences will post 6.57 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Aware Super Pty Ltd as trustee of Aware Super acquired a new position in Neurocrine Biosciences during the first quarter valued at approximately $18,020,000. State of Michigan Retirement System raised its position in Neurocrine Biosciences by 2.5% during the first quarter. State of Michigan Retirement System now owns 24,181 shares of the company's stock valued at $3,186,000 after purchasing an additional 600 shares in the last quarter. Principal Financial Group Inc. raised its position in Neurocrine Biosciences by 5.2% during the first quarter. Principal Financial Group Inc. now owns 238,161 shares of the company's stock valued at $31,375,000 after purchasing an additional 11,784 shares in the last quarter. Chicago Partners Investment Group LLC raised its position in Neurocrine Biosciences by 37.9% during the first quarter. Chicago Partners Investment Group LLC now owns 7,389 shares of the company's stock valued at $969,000 after purchasing an additional 2,030 shares in the last quarter. Finally, Diversify Wealth Management LLC acquired a new position in Neurocrine Biosciences during the first quarter valued at approximately $210,000. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Q1 results beat consensus — Neurocrine reported EPS of $1.94 and ~ $811M net product sales (up ~44% YoY), ahead of Street estimates and driven by product momentum. Neurocrine Biosciences Reports First-Quarter 2026 Financial Results
• Positive Sentiment: INGREZZA sales powered the upside — multiple outlets highlight that INGREZZA net sales beat expectations and are the core driver of the quarter, supporting management’s reaffirmed 2026 INGREZZA sales guidance of $2.7–$2.8B. Neurocrine Biosciences surges 8% as INGREZZA sales drive better-than-expected Q1 results
• Positive Sentiment: M&A expands rare‑disease footprint — Neurocrine announced a definitive agreement to acquire Soleno Therapeutics, adding VYKAT XR (diazoxide choline) for hyperphagia in Prader‑Willi syndrome, a potential new commercial franchise. Neurocrine Biosciences Reports First-Quarter 2026 Financial Results
• Positive Sentiment: Pipeline progress — The company initiated a Phase 2 study of NBI‑1117570 (M1/M4 agonist) in adults with schizophrenia, signaling continued R&D advancement beyond its core neurology franchise. Neurocrine Biosciences Reports First-Quarter 2026 Financial Results
• Neutral Sentiment: Analyst stance — The consensus analyst recommendation is roughly a “Moderate Buy,” which supports investor confidence but still implies varying upside expectations. Neurocrine Biosciences Given Average Recommendation of "Moderate Buy" by Analysts
• Neutral Sentiment: Upcoming investor engagement — Management is scheduled to present at the Bank of America Health Care Conference next week, which could provide additional color on guidance and M&A integration. Neurocrine Biosciences to Present at the Bank of America Health Care Conference 2026
• Neutral Sentiment: Awareness/PR activity — A company survey highlighting the burden of tardive dyskinesia may help commercial uptake and stakeholder awareness but is primarily a marketing/advocacy play. Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment
• Negative Sentiment: Valuation and expectations — NBIX trades at a premium (P/E near ~29) after the rally; high expectations mean future misses or slower INGREZZA growth could pressure the share price. Neurocrine Biosciences Stock Info

Neurocrine Biosciences Company Profile

Neurocrine Biosciences NASDAQ: NBIX is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine's operations encompass drug discovery, clinical development and commercialization activities.

The company's lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.